CeriBell (CBLL) – Research Analysts’ Weekly Ratings Changes

CeriBell (NASDAQ: CBLL) recently received a number of ratings updates from brokerages and research firms:

• 8/18/2026 – CeriBell was upgraded by Barclays PLC to “neutral”.
• 8/18/2026 – CeriBell had its price target raised by BTIG Research from $28.00 to $30.00. They now have a “buy” rating on the stock.
• 8/13/2026 – CeriBell was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/11/2026 – CeriBell had its price target raised by Canaccord Genuity Group Inc. from $25.00 to $26.00. They now have a “buy” rating on the stock.
• 8/11/2026 – CeriBell had its “buy” rating reaffirmed by BTIG Research. They now have a $28.00 price target on the stock.
• 7/14/2026 – CeriBell was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/29/2026 – CeriBell was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insider Activity

In related news, Director Joseph Michael Taylor sold 13,095 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $23.40, for a total transaction of $306,423.00. Following the completion of the sale, the director directly owned 48,478 shares in the company, valued at approximately $1,134,385.20. This trade represents a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director William W. Burke sold 2,207 shares of CeriBell stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $19.84, for a total transaction of $43,786.88. Following the transaction, the director directly owned 23,022 shares in the company, valued at $456,756.48. This trade represents a 8.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 313,780 shares of company stock valued at $6,241,749 in the last quarter. Insiders own 17.70% of the company’s stock.

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.